Etiometry Receives FDA Clearance for Cardiogenic Shock Tracking

The new AI-powered software automates classification and monitoring of this life-threatening condition.

Apr. 8, 2026 at 5:01pm

Got story updates? Submit your updates here. ›

A translucent X-ray image of a human heart, with the chambers and valves glowing faintly in shades of blue and purple, suggesting the effects of cardiogenic shock.Etiometry's new AI-powered software aims to provide clinicians with real-time insights to better identify and manage cardiogenic shock, a severe heart condition.Boston Today

Etiometry, a Boston-based medical technology company, has received the first-ever FDA clearance for its software that automates the classification and tracking of cardiogenic shock, a severe and potentially fatal condition where the heart is unable to pump enough blood to the body.

Why it matters

Cardiogenic shock is a medical emergency that requires rapid diagnosis and treatment, but it can be challenging for healthcare providers to consistently identify and monitor. Etiometry's AI-powered software aims to improve patient outcomes by providing real-time insights to clinicians.

The details

Etiometry's software uses advanced algorithms to continuously analyze patient data from various medical devices and electronic health records. It can automatically detect signs of cardiogenic shock, classify its severity, and track the patient's condition over time. This allows doctors and nurses to quickly identify at-risk patients and make more informed treatment decisions.

  • Etiometry received FDA clearance for its cardiogenic shock software on April 8, 2026.

The players

Etiometry

A Boston-based medical technology company that develops AI-powered software for hospital use.

Got photos? Submit your photos here. ›

What they’re saying

“This FDA clearance is a major milestone for Etiometry and for the future of patient monitoring and care. Our technology gives clinicians powerful new tools to identify and manage cardiogenic shock, which will ultimately save lives.”

— Dr. Alok Mathur, Chief Medical Officer, Etiometry

The takeaway

Etiometry's new FDA-cleared software represents an important advancement in the use of AI and automation to enhance clinical decision-making and improve outcomes for patients experiencing life-threatening conditions like cardiogenic shock.